EMA Approves Asthma Treatment for Patients Five and Older

The European Medicines Agency approved the Flutiform pressurized metered dose inhaler (pMDI) for use as a twice-daily maintenance asthma treatment in children five years of age or older.

Flutiform pMDI pairs the corticosteroid fluticasone propionate and the long acting beta agonist formoterol. The combination therapy has been available to patients aged 12 years and older in the UK since 2012.

The inhaled corticosteroid reduces swelling and inflammation in the patient’s lungs, while the beta agonist relaxes airways, making it easier for patients to breathe.